1. Home
  2. XNET vs RLMD Comparison

XNET vs RLMD Comparison

Compare XNET & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XNET
  • RLMD
  • Stock Information
  • Founded
  • XNET 2003
  • RLMD 2004
  • Country
  • XNET China
  • RLMD United States
  • Employees
  • XNET N/A
  • RLMD N/A
  • Industry
  • XNET Computer Software: Prepackaged Software
  • RLMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • XNET Technology
  • RLMD Health Care
  • Exchange
  • XNET Nasdaq
  • RLMD Nasdaq
  • Market Cap
  • XNET 131.8M
  • RLMD 110.6M
  • IPO Year
  • XNET 2014
  • RLMD N/A
  • Fundamental
  • Price
  • XNET $1.87
  • RLMD $2.80
  • Analyst Decision
  • XNET
  • RLMD Hold
  • Analyst Count
  • XNET 0
  • RLMD 2
  • Target Price
  • XNET N/A
  • RLMD $7.50
  • AVG Volume (30 Days)
  • XNET 119.6K
  • RLMD 135.5K
  • Earning Date
  • XNET 11-14-2024
  • RLMD 11-07-2024
  • Dividend Yield
  • XNET N/A
  • RLMD N/A
  • EPS Growth
  • XNET 23.02
  • RLMD N/A
  • EPS
  • XNET 0.23
  • RLMD N/A
  • Revenue
  • XNET $316,007,000.00
  • RLMD N/A
  • Revenue This Year
  • XNET N/A
  • RLMD N/A
  • Revenue Next Year
  • XNET N/A
  • RLMD N/A
  • P/E Ratio
  • XNET $8.20
  • RLMD N/A
  • Revenue Growth
  • XNET N/A
  • RLMD N/A
  • 52 Week Low
  • XNET $1.45
  • RLMD $1.88
  • 52 Week High
  • XNET $2.41
  • RLMD $7.22
  • Technical
  • Relative Strength Index (RSI)
  • XNET 44.55
  • RLMD 27.58
  • Support Level
  • XNET $2.01
  • RLMD $2.74
  • Resistance Level
  • XNET $1.98
  • RLMD $3.43
  • Average True Range (ATR)
  • XNET 0.11
  • RLMD 0.20
  • MACD
  • XNET -0.03
  • RLMD -0.06
  • Stochastic Oscillator
  • XNET 11.99
  • RLMD 8.50

About XNET Xunlei Limited

Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Share on Social Networks: